Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

Burger, Robert A.

doi:10.3802/jgo.2010.21.1.3

Cited by 26 publications

(21 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Although several studies have targeted the VEGF family in ovarian cancer (15)(16)(17)(18), another effective approach for the treatment of various cancers are peptides derived from the TSR antiangiogenic domain of TSP-1 (19). Numerous studies have shown the antiangiogenic and antitumor effects of 3TSR (20)(21)(22) and ABT-510 (11,23,24) and have shown safety and efficacy in animal and human studies (12,13,25,26).…”

Section: Discussionmentioning

confidence: 99%

ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

Campbell

Greenaway

Henkin

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy and is often not diagnosed until late stages due to its asymptomatic nature. Women diagnosed with EOC typically undergo surgical debulking followed by chemotherapy; however, disease recurrence often occurs. In this study, we evaluated the ability of the thrombospondin-1 mimetic peptide, ABT-898, to regress established, late-stage tumors in a mouse model of human EOC. Ovarian tumors were induced and ABT-898 treatment was initiated at time points that were representative of late stages of the disease to study tumor regression. ABT-898 induced tumor regression and reduced the morbidity of treated animals compared with controls. Analysis of tumors from ABT-898-treated animals showed reduced abnormal tumor vasculature, decreased expression of the proangiogenic compound VEGF, and reduced tumor tissue hypoxia. ABT-898 treatment initiated at late-stage disease also significantly prolonged disease-free survival compared with control animals. Results from this study show that ABT-898 is capable of regressing established ovarian tumors in an animal model of the disease. As most women are detected at advanced stage EOC, ABT-898 may improve our treatment of ovarian cancer. Mol Cancer Ther; 10(10); 1876-85. Ó2011 AACR.

show abstract

Section: Discussionmentioning

confidence: 99%

ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

Campbell

Greenaway

Henkin

et al. 2011

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…During the past decade, role of VEGF targeted therapy was mentioned in gynecologic malignancies [17]. Most studies concentrated on ovarian cancer, while a few trials of cervical cancer are ongoing.…”

Section: Discussionmentioning

confidence: 99%

Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor (VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients

Katanyoo¹,

Rongsriyam²,

Chongtanakon³

2013

JCT

View full text Add to dashboard Cite

Objective: To evaluate the association between pretreatment levels of serum vascular endothelial growth factor (VEGF) and long-term treatment outcomes in patients with locally advanced cervical cancer (LACC). Methods: Thirty-nine patients diagnosed with LACC (stage IIB-IVA) and obtaining blood for serum VEGF were identified. All patients received complete treatment as radical radiotherapy with or without concurrent chemotherapy. Surveillance for all patients was every 3 months during the first 2 years, and every 6 months later. Results: Mean age of 39 patients was 52.3 ± 10.8 years old. Twenty-three patients (59.0%) had stage IIB, and 16 patients (41.0%) had stage IIIB. Histological cell type was mostly squamous cell carcinoma (89.7%). The median and 75 th percentile level of serum VEGF were 610.2 pg/ml (0.0-4067.2 pg/ml) and 825.6 pg/ml, respectively. At median follow-up of 37.0 months (range, 26.8-46.3 months), the 3-year OS rate was 78.6%. Clinical stage (p = 0.04) and 75 th percentile of VEGF level (p = 0.04) were impacted on OS in univariable analysis. The 3-year OS of patients in stage IIB with serum VEGF of ≤825.6 pg/ml and of > 825.6 pg/ml was slightly different, 94.4% and 80.0% respectively (p = 0.34), whereas there were many differences in stage IIIB, 71.4% and 25.0% in patients with serum VEGF of ≤825.6 pg/ml and of >825.6 pg/ml respectively (p = 0.05). Conclusion: High pretreatment serum VEGF level has an influence on OS for LACC. It is potentially used as a predictive factor, especially in patients stage IIIB, in order to provide efficient treatment and improve survival outcomes in the future.

show abstract

“…However, no difference in OS was observed. Bevacizumab treatment was well tolerated, with the major AEs attributed to chemotherapy 126 . In another Phase 3 trial, patients with EOC were treated with carboplatin and paclitaxel alone or in combination with concurrent bevacizumab.…”

Section: Monoclonal Antibodies For the Treatment Of Ovarian Cancermentioning

confidence: 99%

Therapeutic targets and new directions for antibodies developed for ovarian cancer

Bax

Josephs

Pellizzari

et al. 2016

mAbs

View full text Add to dashboard Cite

Antibody therapeutics against different target antigens are widely used in the treatment of different malignancies including ovarian carcinomas, but this disease still requires more effective agents. Improved understanding of the biological features, signaling pathways, and immunological escape mechanisms involved in ovarian cancer has emerged in the past few years. These advances, including an appreciation of the cross-talk between cancer cells and the patient's immune system, have led to the identification of new targets. In turn, potential antibody treatments with various mechanisms of action, including immune activation or toxin-delivery, that are directed at these targets have been developed. Here, we identify established as well as novel targets for antibodies in ovarian cancer, and discuss how they may provide fresh opportunities to identify interventions with enhanced therapeutic potential.

show abstract

Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies

Cited by 26 publications

References 59 publications

ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

ABT-898 Induces Tumor Regression and Prolongs Survival in a Mouse Model of Epithelial Ovarian Cancer

Association between Pretreatment Levels of Serum Vascular Endothelial Growth Factor (VEGF) and Survival Outcomes in Locally Advanced Cervical Cancer Patients

Therapeutic targets and new directions for antibodies developed for ovarian cancer

Contact Info

Product

Resources

About